• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.

    8/7/25 11:36:20 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care
    Get the next $BBNX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Beta Bionics, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    08659B102

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Perceptive Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,593,608.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,593,608.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,593,608.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.68 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Joseph Edelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,593,608.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,593,608.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,593,608.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.68 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Perceptive Life Sciences Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,593,608.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,593,608.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,593,608.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.68 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Beta Bionics, Inc.
    (b)Address of issuer's principal executive offices:

    11 Hughes, Irvine, CA 92618
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.0001 per share (the "Common Stock") of Beta Bionics, Inc. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
    (c)Citizenship:

    Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    08659B102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 43,348,840 shares of Common Stock outstanding as of March 1, 2025, as reported in the Issuer's Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on March 28, 2025. The Master Fund directly holds, and directly held as of March 31, 2025, 1,593,608 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares. This Amendment No. 1 to Schedule 13G restates the holdings of the Master Fund as of the date hereof, and as of the date reported on the Reporting Persons' initial filing on Schedule 13G.
    (b)Percent of class:

    Perceptive Advisors: 3.68% Mr. Edelman: 3.68% Master Fund: 3.68%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (ii) Shared power to vote or to direct the vote:

    Perceptive Advisors: 1,593,608 Mr. Edelman: 1,593,608 Master Fund: 1,593,608

     (iii) Sole power to dispose or to direct the disposition of:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Perceptive Advisors: 1,593,608 Mr. Edelman: 1,593,608 Master Fund: 1,593,608

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Perceptive Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:08/07/2025
     
    Joseph Edelman
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman
    Date:08/07/2025
     
    Perceptive Life Sciences Master Fund, Ltd.
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:08/07/2025
    Get the next $BBNX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBNX

    DatePrice TargetRatingAnalyst
    6/16/2025$26.00Buy
    Truist
    6/12/2025$30.00Buy
    Lake Street
    5/30/2025$16.00Neutral
    Goldman
    5/30/2025$20.00Outperform
    Wolfe Research
    2/24/2025Buy
    BofA Securities
    2/24/2025$30.00Buy
    Lake Street
    2/24/2025$25.00Buy
    Stifel
    2/24/2025$26.00Overweight
    Piper Sandler
    More analyst ratings

    $BBNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Mensinger Mike bought $566,950 worth of shares (33,350 units at $17.00), converted options into 15,107 shares, exercised 10,575 in-the-money shares at a strike of $0.02 and sold $221 worth of shares (13 units at $17.00) (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    2/3/25 8:30:15 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Large owner Wellington Hadley Harbor Aggregator Iv, L.P. converted options into 2,901,599 shares and bought $17,000,000 worth of shares (1,000,000 units at $17.00) (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    2/3/25 4:49:52 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Russell Steven Jon sold $18,588 worth of shares (1,039 units at $17.89), decreasing direct ownership by 1% to 72,032 units (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    6/4/25 7:30:17 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Chief Product Officer Mensinger Mike sold $19,948 worth of shares (1,115 units at $17.89), decreasing direct ownership by 1% to 92,904 units (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    6/4/25 7:30:15 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Hopman Mark sold $15,529 worth of shares (868 units at $17.89), decreasing direct ownership by 2% to 34,132 units (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    6/4/25 7:30:19 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.

    SCHEDULE 13G/A - Beta Bionics, Inc. (0001674632) (Subject)

    8/13/25 4:57:20 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Beta Bionics Inc.

    SCHEDULE 13G - Beta Bionics, Inc. (0001674632) (Subject)

    8/7/25 3:20:42 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.

    SCHEDULE 13G/A - Beta Bionics, Inc. (0001674632) (Subject)

    8/7/25 11:36:20 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance

    IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2025 and raised its full year guidance for the year ending December 31, 2025. Second Quarter 2025 Financial Results & Key Metrics Net sales of $23.2 million, up 54% compared to $15.0 million in the second quarter of 2024. Durable Medical Equipment (DME) channel net sales of $18.6 million, up 31% compared to $14.3 million in the second quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $4.6 million, up 498% compared to $0.8 million in the second

    7/29/25 4:02:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

    Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing

    7/21/25 7:00:00 AM ET
    $BBNX
    $BCAX
    $KMTS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025

    IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2025 financial results after the financial markets close on Tuesday, July 29, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following l

    7/2/25 7:30:00 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Leadership Updates

    Live Leadership Updates

    View All

    Beta Bionics Announces Board Appointment of Gerard Michel

    IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

    3/27/25 4:45:06 PM ET
    $BBNX
    $DCTH
    Medical/Dental Instruments
    Health Care

    $BBNX
    Financials

    Live finance-specific insights

    View All

    Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance

    IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2025 and raised its full year guidance for the year ending December 31, 2025. Second Quarter 2025 Financial Results & Key Metrics Net sales of $23.2 million, up 54% compared to $15.0 million in the second quarter of 2024. Durable Medical Equipment (DME) channel net sales of $18.6 million, up 31% compared to $14.3 million in the second quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $4.6 million, up 498% compared to $0.8 million in the second

    7/29/25 4:02:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025

    IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2025 financial results after the financial markets close on Tuesday, July 29, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following l

    7/2/25 7:30:00 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025

    IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2025 financial results after the financial markets close on Tuesday, May 6, 2025. In connection with the release, management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. You may also access the live c

    4/16/25 4:05:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Beta Bionics with a new price target

    Truist initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $26.00

    6/16/25 7:46:03 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on Beta Bionics with a new price target

    Lake Street initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $30.00

    6/12/25 8:09:02 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Goldman initiated coverage on Beta Bionics with a new price target

    Goldman initiated coverage of Beta Bionics with a rating of Neutral and set a new price target of $16.00

    5/30/25 8:40:02 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care